Fig. 5From: Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patientsThe frequency of ocular adverse events observed in brolucizumab and aflibercept arm throughout the study period of 48Â weeksBack to article page